Regrettably, the conspiracy theory I've been entertaining below could turn out to be one of the plausible explanations for what's happening:
The MHRA (the UK’s drug watchdog) is totally in bed with Big Pharma—probably swapping staff and favors left and right.
The people reviewing DCVax-L don’t seem to care.
I bet they’re not even putting in a full day’s work to get this life-saving cancer vaccine approved fast. Otherwise, it doesn't make sense on such delays.
Meanwhile, brain-cancer patients are dying.
Picture this: you work at the MHRA and make £100,000 a year.
Some shady guy connected to a giant drug company slides you £1 million in secret to “take it easy” and slow the review by just 20%.
You’ve got rent, kids, and Christmas presents to buy—and this drug doesn’t affect anyone you know.
What do you say?
DCVax-L could wreck billions in profits for the big boys who sell pricey, barely-better cancer drugs.
So they whisper in ears, pay “consultants,” and suddenly the little guy’s miracle treatment gets stuck in red tape forever.
Without hard proof of corruption, I can’t explain these endless, inexplicable delays any other way.
The pattern fits too neatly: revolutionary therapies from small biotechs get buried in bureaucracy, while Big Pharma’s me-too drugs sail through.
Coincidence? Or conspiracy? You decide.
Oh, yeah. FU MHRA. My curse on everyone dragging feet on DCVax approval.
Market Data 
Markets 
